Absorbed dose estimates at the cellular level for 186Re and 188Re

Ünak, Perıhan; Çetinkaya, Berkan; Unak, Isin

doi:10.1016/j.radphyschem.2004.10.002

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The half-lives of zirconium-97, 293 tin-126 294 and sodium-24, potassium-42 together with gold-198, 295 have all been re-measured with increased accuracy during the past year, new g-rays found 296 in the decay of excited ruthenium-101 (from [ 98 Mo(a,p) 101 Tc: 101 Tc(b-decay) 101 Ru]) and a comparison made 297 between the K-and L-Auger spectra from the decay of neodymium-140 and indium-111. Revised radiation absorbed dose estimates at the cellular level have been made for rhenium 298 -186 and -188 and also for thallium-201. 299…”

Section: Datamentioning

confidence: 99%

Radiochemistry and radiopharmaceuticals

Urch

Welch

2006

Annu. Rep. Prog. Chem., Sect. A: Inorg. Chem.

View full text Add to dashboard Cite

Following last year's precedent this section of Annual Reports will review not only recent progress in radiochemistry, including isotope production and environmental aspects, but also in the production of radiopharmaceuticals and their use in nuclear medicine for imaging. Radiation chemistry (unless related to the stability of labelled molecules), the use of nuclear activation analysis and the inorganic chemistry of elements that are by their nature, radioactive are all excluded. HighlightsThe IAEA published 1 the results of a wide ranging review of nuclear measurements. Conferences held during 2005 which covered progress in radiochemistry, included the '4th all Polish Conference on Radiochemistry and Nuclear Chemistry' 2 and the '7th Nuclear and Radiochemistry Symposium' 3 whilst a more focused meeting dealt with the production and application of labelled compounds 4 in the oil industry. A couple of very interesting articles appeared during 2005 questioning what exactly is meant by many fundamental 'radiochemical' concepts 5 such as 'specific activity' and 'carrier-free' and indeed how the specific activities 6 of 'no-carrier-added' materials can be determined. The Proceedings of the 16th Symposium on Radiopharmaceutical Chemistry 7 covers advances made in radiopharmaceutical development and applications while the Proceedings of the Society of Nuclear Medicine 8 and the European Society of Nuclear Medicine 9 cover both radiopharmaceutical development and the application in diagnosis and therapy. A critical review has been published 10 on the application of positron emitting nuclides for use as radiopharmaceuticals.

show abstract